NCT00824850

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

Characterization of the Prevnar Infant Long-term Immune Response vs a Prevnar Naive Cohort

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 8 Years – 16 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente (NCKP) health plan.

Conditions

• Pneumococcal Conjugate Vaccine

Interventions

Type	Name	Description
BIOLOGICAL	13-valent Pneumococcal Conjugate Vaccine	single injection, single dose, single site, 0.5 mL per dose.
BIOLOGICAL	13-valent Pneumococcal Conjugate Vaccine	single injection, single dose, single site, 0.5 mL per dose.

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2009-01-19
• Last updated: 2011-11-11
• Results posted: 2011-11-11

Locations

2 sites across 1 country: United States